b"NGS Cancer PanelsCytogenetic identification of chromosome abnormalitiesin AML and other hematologic diseases, respectively. has become essential for the clinical management ofThis comprehensive assay is capable of detecting single patients with leukemia, and it is currently used to helpnucleotide substitutions, insertions, deletions, and gene classify patients into risk groups. With the development rearrangements.of novel genomics technologies, such as Next-Generation Sequencing, numerous new mutations and gene expressionOur MyMRD panel was designed to sensitively capture signatures have been identified. These breakthroughs allowall classes of variants identified in a precisely defined set us to better understand the molecular heterogeneity ofof targets that commonly drive myeloid malignancies hematologic diseases and to better stratify and assess riskincluding AML, MPN, and MDS .for cancer patients. Our MyAML, MyMRD and MyHEME cancer panels are Using these molecular tools, it has become evidentaimed at promoting a broader understanding of patients' that leukemias, lymphomas, and hematologic diseasesclinical responses and outcomes. Panels run at the time are characterized by a remarkable amount of geneticof diagnosis identify both clinically-actionable driver heterogeneity, with individual patients presenting distinctmutations associated with the primary tumor, as welland almost unique combinations of chromosome changesas the subclonal architecture that may be present.and somatically-acquired gene mutations. Temporal specimens collected and tested during thecourse of treatment identify the loss or elimination ofLabPMM offers comprehensive NGS gene panels for AMLdriver mutations, as well as emergence or re-emergenceand other hematological malignancies. Our MyAML of new clones and new potential therapeutic targets. cancer panel is designed to analyze and interpret sequence information in genes known or suspected to be involved 50 LabPMM Services Catalog 2020|51"